Early detection is a primary objective of ovarian cancer research because of its promise for improved quality of life and survival. Five-year survival in women with cancer confined to the ovaries is 95%, but only 25% when the disease has spread outside the ovary; 70% of cases are diagnosed in this advanced stage. It is estimated that this year about 21,550 US women will be diagnosed with ovarian cancer, and 14,600 will die from the disease.1